Variable Monitoring of Veterans with Group 3 Pulmonary Hypertension Treated with Off-Label Pulmonary Vasodilator Therapy.
作者信息
Johnson Shelsey W, Gillmeyer Kari R, Bolton Rendelle E, McCullough Megan B, Qian Shirley X, Maron Bradley A, Klings Elizabeth S, Wiener Renda Soylemez
机构信息
Veterans Affairs Bedford Healthcare System Bedford, Massachusetts.
Veterans Affairs Boston Healthcare System Boston, Massachusetts.
出版信息
Ann Am Thorac Soc. 2022 Jul;19(7):1236-1239. doi: 10.1513/AnnalsATS.202110-1168RL.
Abstract
摘要
相似文献
1
Variable Monitoring of Veterans with Group 3 Pulmonary Hypertension Treated with Off-Label Pulmonary Vasodilator Therapy.对接受标签外肺血管扩张剂治疗的3组肺动脉高压退伍军人进行变量监测。
Ann Am Thorac Soc. 2022 Jul;19(7):1236-1239. doi: 10.1513/AnnalsATS.202110-1168RL.
2
Factors Associated With Potentially Inappropriate Phosphodiesterase-5 Inhibitor Use for Pulmonary Hypertension in the United States, 2006 to 2015.2006年至2015年美国肺动脉高压患者使用磷酸二酯酶-5抑制剂潜在不当的相关因素
Circ Cardiovasc Qual Outcomes. 2020 May;13(5):e005993. doi: 10.1161/CIRCOUTCOMES.119.005993. Epub 2020 May 12.
3
Vasodilator use in precapillary pulmonary hypertension with end stage kidney disease: A single center experience.血管扩张剂在终末期肾病所致毛细血管前性肺动脉高压中的应用：单中心经验
Respir Med. 2021 Nov;188:106596. doi: 10.1016/j.rmed.2021.106596. Epub 2021 Sep 4.
4
[Vasodilator therapy in pulmonary hypertension].
Vnitr Lek. 1986 Oct;32(10):1021-7.
5
Off-label use of pulmonary vasodilators after left ventricular assist device implantation: Calling in the evidence.左心室辅助装置植入术后肺血管扩张剂的超适应证使用：调用证据。
Pharmacol Ther. 2020 Oct;214:107619. doi: 10.1016/j.pharmthera.2020.107619. Epub 2020 Jun 26.
6
Vasodilator therapy for pulmonary hypertension.
N Engl J Med. 1980 May 29;302(22):1261-2.
7
8
[Vasodilator therapy in pulmonary arterial hypertension of unknown cause (primary)].
Arch Inst Cardiol Mex. 1982 May-Jun;52(3):189-90.
9
Hemodynamic evaluation of vasodilator drug therapy in primary pulmonary hypertension.
Am Heart J. 1981 Aug;102(2):300. doi: 10.1016/s0002-8703(81)80025-7.
10
Vasodilator therapy for primary pulmonary hypertension.原发性肺动脉高压的血管扩张剂治疗
Mayo Clin Proc. 1984 Oct;59(10):672-7. doi: 10.1016/s0025-6196(12)62055-2.
引用本文的文献
1
Cluster analysis identifies novel real-world lung disease-pulmonary hypertension subphenotypes: implications for treatment response.聚类分析识别出新型的真实世界肺部疾病-肺动脉高压亚表型：对治疗反应的影响。
ERJ Open Res. 2024 May 20;10(3). doi: 10.1183/23120541.00959-2023. eCollection 2024 May.
2
Real-world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real-world Evidence Working Group.推进肺动脉高压知识的真实世界证据：现状、挑战与机遇。肺血管研究所创新药物开发倡议真实世界证据工作组的共识声明。
Pulm Circ. 2023 Dec 21;13(4):e12317. doi: 10.1002/pul2.12317. eCollection 2023 Oct.
本文引用的文献
1
Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease.左心疾病和肺部疾病相关肺动脉高压退伍军人使用肺血管扩张剂的疗效
Pulm Circ. 2021 Apr 1;11(2):20458940211001714. doi: 10.1177/20458940211001714. eCollection 2021 Apr-Jun.
2
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.特发性肺纤维化相关肺动脉高压患者应用吸入曲前列尼尔治疗
N Engl J Med. 2021 Jan 28;384(4):325-334. doi: 10.1056/NEJMoa2008470. Epub 2021 Jan 13.
3
Factors Associated With Potentially Inappropriate Phosphodiesterase-5 Inhibitor Use for Pulmonary Hypertension in the United States, 2006 to 2015.2006年至2015年美国肺动脉高压患者使用磷酸二酯酶-5抑制剂潜在不当的相关因素
Circ Cardiovasc Qual Outcomes. 2020 May;13(5):e005993. doi: 10.1161/CIRCOUTCOMES.119.005993. Epub 2020 May 12.
4
How Closely Do Clinical Trial Participants Resemble "Real-World" Patients with Groups 2 and 3 Pulmonary Hypertension? A Structured Review.2组和3组肺动脉高压的临床试验参与者与“真实世界”患者的相似程度如何？一项结构化综述。
Ann Am Thorac Soc. 2020 Jun;17(6):779-783. doi: 10.1513/AnnalsATS.202001-003RL.
5
A Concerning Trend for Patients With Pulmonary Hypertension in the Era of Evidence-Based Medicine.循证医学时代肺动脉高压患者的一个令人担忧的趋势。
Circulation. 2019 Apr 16;139(16):1861-1864. doi: 10.1161/CIRCULATIONAHA.118.037613.
6
Pulmonary hypertension in chronic lung disease and hypoxia.慢性肺部疾病与低氧血症相关性肺动脉高压
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01914-2018. Print 2019 Jan.
7
Phosphodiesterase-5 Inhibitor Therapy for Pulmonary Hypertension in the United States. Actual versus Recommended Use.美国的磷酸二酯酶-5 抑制剂治疗肺动脉高压：实际应用与推荐应用。
Ann Am Thorac Soc. 2018 Jun;15(6):693-701. doi: 10.1513/AnnalsATS.201710-762OC.
8
Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis.世界卫生组织III组肺动脉高压中PAH特异性疗法的长期使用：一项系统评价和荟萃分析。
Pulm Circ. 2017 Mar 24;7(1):145-155. doi: 10.1086/690017. eCollection 2017 Mar.
9
The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups.吉森肺动脉高压注册研究：肺动脉高压亚组的生存情况。
J Heart Lung Transplant. 2017 Sep;36(9):957-967. doi: 10.1016/j.healun.2017.02.016. Epub 2017 Feb 17.
10
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).2015 ESC/ERS 肺动脉高压诊断与治疗指南：欧洲心脏病学会（ESC）和欧洲呼吸学会（ERS）肺动脉高压诊断与治疗工作组制定：该指南得到了欧洲儿科和先天性心脏病协会（AEPC）以及国际心肺移植学会（ISHLT）的认可。
Eur Respir J. 2015 Oct;46(4):903-75. doi: 10.1183/13993003.01032-2015. Epub 2015 Aug 29.
Zotero 插件